Acute myeloid leukemia is notorious for its complex genetic landscape and resistance to conventional treatments, leading to high relapse rates and poor prognoses. Identifying molecular Achilles’ heels in AML cells remains a critical objective for researchers aiming to develop more effective treatments. The focus on MYBL2, a transcription factor integral to cell cycle progression and DNA replication, has emerged as a pivotal point of interest due to its overexpression in various malignancies and its role in orchestrating cellular proliferation and genomic stability.

The team employed a combination of advanced genomic analyses, gene editing technologies, and cellular assays to comprehensively dissect the role of MYBL2 in AML. Their meticulous experiments revealed that MYBL2 is distinctly upregulated in AML cells compared to normal hematopoietic cells, underscoring its potential as a biomarker and therapeutic target. Functional disruption of MYBL2 through RNA interference and CRISPR-Cas9-mediated knockdown led to pronounced inhibition of leukemic cell growth, highlighting the critical dependency of AML cells on this regulator.

Mechanistically, MYBL2 exerts its oncogenic influence by modulating the expression of genes central to the G2/M phase transition and mitotic spindle assembly. This regulatory network ensures the faithful segregation of chromosomes during cell division, a process often hijacked by cancer cells to sustain relentless proliferation. The data indicated that loss of MYBL2 triggered cell cycle arrest, impaired DNA repair pathways, and induced apoptotic cascades, collectively crippling the survival machinery of AML cells.

One of the study’s captivating findings is the apparent selectivity of MYBL2 inhibition; normal bone marrow cells exhibited a remarkable resilience to MYBL2 suppression, suggesting a favorable therapeutic window. This differential sensitivity posits MYBL2 as a viable cancer-specific vulnerability that could be exploited to minimize collateral damage to healthy tissues, a perennial challenge in oncology treatment paradigms.

Beyond its role in leukemogenesis, MYBL2 was implicated in maintaining the stem-like properties of leukemic stem cells (LSCs), which are often responsible for disease persistence and relapse. Targeting MYBL2 compromised the self-renewal capacity of these notoriously refractory LSCs, offering hope for eradicating the reservoir of cells that evade conventional chemotherapies.

The researchers also conducted nuanced analyses of patient-derived AML samples, corroborating the clinical relevance of their findings. Elevated MYBL2 expression was consistently associated with aggressive disease phenotypes and poorer clinical outcomes. This correlation further cements the prognostic importance of MYBL2 and underscores the urgency of developing MYBL2-directed therapies for AML patients.

Intriguingly, the study delved into the interplay between MYBL2 and cell cycle checkpoint kinases, revealing that MYBL2 acts as a central node integrating cell cycle signals with DNA damage responses. This insight elucidates how AML cells harness MYBL2 to navigate genotoxic stress, thereby evading apoptosis and sustaining malignancy. The dual regulatory functions of MYBL2 position it as a master regulator in AML pathobiology.

From a therapeutic development standpoint, the identification of MYBL2 dependency invites the exploration of small molecule inhibitors or peptide-based agents capable of disrupting MYBL2 function. While direct MYBL2 inhibitors are not yet available, the study propels the imperative to design compounds that can modulate its activity or destabilize its interaction with critical cofactors within leukemic cells.

Furthermore, the research opens the door to combinatorial treatment strategies. MYBL2 inhibition could synergize with existing chemotherapeutics or novel agents targeting complementary pathways such as DNA damage repair, apoptosis, or epigenetic modifications. Such combination regimens may overcome resistance mechanisms and enhance treatment efficacy in AML.

The findings also invigorate the broader field of cancer biology by demonstrating a paradigm wherein cell cycle regulators like MYBL2 transcend their canonical roles and act as oncogenic drivers. This conceptual advance prompts reevaluation of cell cycle factors in other malignancies and encourages the pursuit of cell cycle-targeted therapies beyond AML.

The translational potential of this study is underscored by the feasibility of incorporating MYBL2 expression profiling into clinical diagnostics. Stratifying patients based on MYBL2 status could refine prognostic models and personalize treatment approaches, aligning with the principles of precision oncology.

In summary, the work of Küchler and colleagues highlights MYBL2 as an indispensable regulator and exploitable vulnerability in AML. Their comprehensive investigation offers a promising blueprint for future research and drug development aimed at mitigating the devastating impact of acute myeloid leukemia. With continued efforts, targeting MYBL2 may transition from bench to bedside, heralding a new era in leukemia therapeutics.

As AML remains one of the most challenging hematological cancers, this discovery bears immense significance and hope for patients and clinicians alike. It underscores the power of molecular research to unravel disease intricacies and the relentless pursuit of innovative treatment paradigms in oncology.

Subject of Research: Acute Myeloid Leukemia, Cell Cycle Regulation, MYBL2

Article Title: Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia

Article References:
Küchler, S., Brilloff, S., Schäfer, S. et al. Cell cycle regulator MYBL2 is a distinct vulnerability in acute myeloid leukemia. Cell Death Discov. 11, 470 (2025). https://doi.org/10.1038/s41420-025-02810-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02810-4

Fundamentally, polyamines promote cell cycle progression by modulating the expression and activity of cyclins and cyclin-dependent kinases (CDKs). Evidence from both solid tumors and hematological malignancies indicates that polyamine biosynthesis enzyme ornithine decarboxylase (ODC) supports the transition from G1 to S phase by upregulating cyclins A, D, and E, alongside CDK4. In HL-60 leukemia cells, ODC overexpression was found to overcome chemotherapeutic-induced cell cycle arrest typically observed in G1 or G2/M phases, effectively pushing cells to proliferate despite cytotoxic stress. Conversely, restriction of polyamines in T-cell acute lymphoblastic leukemia (T-ALL) models induces G1 arrest by upregulating CDK inhibitors CDKN1A and CDKN1B, a process mediated by tumor suppressor protein p53. These observations underscore a dual capacity for polyamines to both fuel leukemic cell proliferation and modulate cell cycle checkpoints in response to stress.

Polyamines also confer a protective advantage against cell death mechanisms. In vitro experiments have shown that supplementation with putrescine or enforced ODC expression can reverse apoptosis triggered by chemotherapy in HL-60 cells. The protective effect involves suppression of pro-apoptotic signals like cytochrome c release and reactive oxygen species (ROS) generation, as well as maintenance of mitochondrial membrane potential and preservation of anti-apoptotic protein BCL-2 levels. Such data suggest that polyamine metabolism not only affects cell cycle kinetics but also buffers leukemic cells from lethal insults, potentially contributing to chemoresistance.

One of the most fascinating biochemical roles of polyamines lies in the post-translational modification known as hypusination, uniquely affecting the eukaryotic translation initiation factor 5A (eIF5A). This two-step enzymatic process converts a specific lysine residue into hypusine, with the intermediate deoxyhypusine formed by deoxyhypusine synthase (DHS) and subsequently hydroxylated by deoxyhypusine hydroxylase (DOHH). Spermidine provides the essential aminobutyl group for this modification, directly linking polyamine metabolism to hypusination. Hypusinated eIF5A acts as a critical facilitator of translation elongation and has been implicated in cancer cell survival and drug resistance, especially in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Inhibition of hypusination sensitizes leukemic cells to chemotherapeutic agents such as daunorubicin and vincristine, further underscoring its therapeutic potential.

Beyond translation regulation, spermidine is a notable inducer of autophagy, a cellular recycling process essential for maintaining homeostasis under metabolic stress. Spermidine influences autophagy by decreasing acetyl-CoA levels, a metabolite known to inhibit autophagic flux, via its conversion into acetylated polyamines and by activating histone acetyltransferases (HATs). Moreover, spermidine promotes the selective translation of transcription factors like TFEB through hypusinated eIF5A, which then orchestrates lysosomal biogenesis and autophagy gene expression. In AML, repression of TFEB by the oncogene MYC can inhibit autophagic tumor suppressor pathways, linking polyamine metabolism to the regulation of leukemic blast differentiation and death through epigenetic mechanisms involving DNA demethylation mediated by the IDH1/IDH2-TET2 axis.

Histone deacetylase 10 (HDAC10) has emerged as a modulator of autophagy by catalyzing the hydrolysis of N8-acetylspermidine back to spermidine, maintaining intracellular polyamine pools. In certain malignancies, including colon cancer and cervical carcinoma, this enzymatic activity sustains cell growth under conditions of polyamine restriction. Intriguingly, HDAC10 also contributes to therapy resistance in AML models harboring internal tandem duplications in the FLT3 gene (FLT3-ITD), a mutation associated with poor prognosis. Combined pharmacological inhibition of HDAC10 and FLT3 demonstrates synergistic effects on reducing leukemic cell viability, hinting at a potential axis where polyamine metabolism intersects with autophagy and signal transduction in resistant leukemia phenotypes.

At the nexus of metabolic signaling, polyamines influence protein phosphorylation events by virtue of their electrostatic interaction with nucleotide triphosphates such as ATP and GTP. This interaction enables the regulation of receptor tyrosine kinases, including insulin receptor isoform A and insulin-like growth factor 1 receptor (IGF1R), both abundantly expressed in more than 80% of AML cases. These receptors activate downstream pathways, notably AKT and MEK1/2, fostering leukemic cell survival under nutrient-limited conditions. Recent studies describe an AML-associated insulin-resistant metabolic state characterized by decreased circulating insulin and increased glucose availability, orchestrated by leukemia-induced secretion of insulin-like growth factor binding protein 1 (IGFBP1) from adipose tissue and modulated by gut microbiota metabolites. Polyamines may modulate these signaling axes, reflecting a complex interplay between metabolism and leukemic cell adaptability.

In addition to insulin signaling, polyamines regulate pathways tied to steroid hormone receptors and growth factor receptors. Experimental evidence demonstrates that ODC inhibition diminishes estrogen receptor (ER) expression and activity in breast cancer cells, implicating polyamines in modulating tyrosine phosphorylation of critical adaptor proteins such as Shc. Similarly, androgen receptor (AR) activation is suppressed following ODC silencing in prostate cancer models dependent on androgen signaling. These observations suggest that polyamine metabolism may broadly influence receptor-mediated signal transduction, not only in solid tumors but potentially in leukemias where such pathways are aberrantly activated.

The oxidative metabolism of polyamines contributes to cellular stress responses through the generation of potentially toxic byproducts, including aldehydes and hydrogen peroxide (H2O2). These oxidative metabolites activate the nuclear factor erythroid 2-related factor 2 (NRF2) pathway, which in turn upregulates an array of detoxifying enzymes, such as glutathione S-transferases (GSTA1 and GSTM1), NAD(P)H quinone dehydrogenase 1 (NQO1), and UDP glucuronosyltransferase family 1 member A6 (UGT1A6). In AML, activation of NRF2 and its downstream targets is not only driven by oxidative stress but is also enhanced by mutations in DNA methyltransferase 3A (DNMT3A), particularly the R882H variant. This mutation impairs both DNA methylation efficiency and target specificity, potentially linking epigenetic dysregulation with altered polyamine metabolism and redox homeostasis.

Therapeutically, modulation of the NRF2 pathway is of significant interest. Venetoclax combined with hypomethylating agents (HMAs) reverses decitabine-induced NRF2 nuclear translocation and reduces antioxidant enzyme expression in AML, enhancing anti-leukemic efficacy. In pediatric B-cell ALL, elevated NRF2 expression correlates with chemoresistance, influencing sensitivity to vincristine. These findings posit that polyamine-driven redox regulation has profound implications for treatment response and resistance mechanisms in acute leukemias.

Polyamine catabolic enzymes spermine oxidase (SMOX) and polyamine oxidase (PAOX) generate hydrogen peroxide during the degradation of polyamines, promoting oxidative stress that can trigger ferroptosis—a regulated form of cell death characterized by lipid peroxidation. Ferroptosis induction leads to iron overload and activation of WNT/MYC signaling pathways, which in turn upregulate ODC expression and boost polyamine biosynthesis. This positive feedback loop sustains high polyamine levels within leukemic cells, offering a potential vulnerability that could be exploited therapeutically. Notably, supplementation with polyamines enhances the sensitivity of various cancer models to radiotherapy and chemotherapy by augmenting ferroptotic cell death mechanisms.

The multifaceted roles of polyamines in acute leukemias—from controlling cell cycle and apoptosis to regulating epigenetic modifiers, autophagy, signal transduction, and oxidative stress responses—place these metabolites at a critical crossroads of malignancy biology. Given the frequency of MYC overexpression in both AML and ALL, and the modulation of key pathways by polyamines, targeting polyamine metabolism emerges as a promising strategy to overcome drug resistance and improve patient outcomes. Ongoing research aimed at dissecting the nuanced interplay between polyamine metabolism and leukemic signaling networks holds the potential to uncover novel therapeutic interventions tailored to exploit these metabolic vulnerabilities.

In conclusion, the expanding understanding of polyamine-mediated processes in acute leukemias not only illuminates fundamental mechanisms of leukemogenesis but also opens new avenues for metabolic and epigenetic therapies. As polyamines interlink diverse cellular pathways, their manipulation could shift the paradigm of leukemia treatment, offering hope for more effective and less toxic therapeutic regimens. Ultimately, integrating knowledge of polyamine biology with advances in molecular targeting may pave the way for innovative approaches to combat leukemia’s persistence and relapse.

Subject of Research: Polyamines in acute leukemias and their role at the interface of cell metabolism and epigenetic regulation.

Article Title: Polyamines at the crossroad between cell metabolism and epigenetic regulation in acute leukemias.

Article References:
Pirini, F., Ferrari, A., Jandoubi, M. et al. Polyamines at the crossroad between cell metabolism and epigenetic regulation in acute leukemias. Cell Death Discov. 11, 301 (2025). https://doi.org/10.1038/s41420-025-02573-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02573-y